Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this study is to collect biologically based data for defining predictors and correlates of the effects of ALTO-100.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ALTO-100 | Experimental | ALTO-100 PO tablet, daily dosing 8 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ALTO-100 PO tablet | Drug | one tablet twice daily |
|
| Measure | Description | Time Frame |
|---|---|---|
| To understand the relationship between baseline biology and clinical outcome with ALTO-100 using the Montgomery-Ã…sberg Depression Rating Scale (MADRS) | The Montgomery-Ã…sberg Depression Rating Scale (MADRS) measures the severity of depression where smaller scores indicate less depression and higher scores suggest more severe depression. Possible scores for this 10 item version range from 0 to 60. The change from baseline to the end of the study is the primary outcome. | Measured 5 times over 8 weeks |
| To understand the relationship between baseline biology and clinical outcome with ALTO-100 using the Clinical Global Impression scale - Severity (CGI-S) | The Clinical Global Impression scale - Severity (CGI-S) measures the severity of psychopathology in general where smaller scores indicate less illness and higher scores suggest more severe illness. Possible scores for this scale range from 1 to 7. The change from baseline to the end of the study is the primary outcome. | Measured 5 times over 8 weeks |
| To understand the relationship between baseline biology and clinical outcome with ALTO-100 using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) | The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) measures the severity of PTSD where smaller scores indicate less severe PTSD and higher scores suggest more severe PTSD. Possible scores for this 30 item version range from 0 to 120. The change from baseline to the end of the study is the primary outcome. | Measured 3 times over 8 weeks |
| Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability of ALTO-100 | An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. | From the signing of the ICF until the follow-up visit (up to 12 weeks) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Site 136 | Tempe | Arizona | 85284 | United States | ||
| Site 139 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Number of Participants With Clinically Significant Vital Signs Abnormalities as a Measure of Safety and Tolerability of ALTO-100 | Vital signs measured include blood pressure, heart rate, respiratory rate, temperature, and weight. | From the signing of the ICF until the end-of-treatment visit (up to 11 weeks) |
| Number of Participants With Clinically Significant Laboratory Abnormalities as a Measure of Safety and Tolerability of ALTO-100 | Blood samples for serum chemistry and hematology will be collected for clinical laboratory testing. | From the signing of the ICF until the end-of-treatment visit (up to 11 weeks) |
| Little Rock |
| Arkansas |
| 72211 |
| United States |
| Site 141 | Costa Mesa | California | 92626 | United States |
| Site 118 | Fresno | California | 93703 | United States |
| Site 116 | Martinez | California | 94553 | United States |
| Site 116 | Mather | California | 95655 | United States |
| Site 150 | Boca Raton | Florida | 33431 | United States |
| Site 112 | Doral | Florida | 33172 | United States |
| Site 155 | Elgin | Illinois | 60123 | United States |
| Site 137 | Noblesville | Indiana | 46060 | United States |
| Site 151 | Baltimore | Maryland | 21229 | United States |
| Site 109 | Belmont | Massachusetts | 02478 | United States |
| Site 108 | Jackson | Mississippi | 39216 | United States |
| Site 142 | Lincoln | Nebraska | 68526 | United States |
| Site 144 | Las Vegas | Nevada | 89102 | United States |
| Site 146 | Middleburg Heights | Ohio | 44130 | United States |
| Site 147 | Fort Worth | Texas | 76104 | United States |
| Site 148 | Fort Worth | Texas | 76244 | United States |
| Site 120 | Houston | Texas | 77054 | United States |
| Site 113 | Houston | Texas | 77090 | United States |
| Site 121 | Draper | Utah | 84020 | United States |
| Site 105 | Seattle | Washington | 98104 | United States |
| NTC Seattle (105a) | Tacoma | Washington | 98104 | United States |
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Dec 24, 2025 | Jan 14, 2026 | 7 |
| ID | Term |
|---|---|
| D003865 | Depressive Disorder, Major |
| D013313 | Stress Disorders, Post-Traumatic |
| ID | Term |
|---|---|
| D003866 | Depressive Disorder |
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
| D040921 | Stress Disorders, Traumatic |
| D000068099 | Trauma and Stressor Related Disorders |
Not provided
Not provided